Diagnostic performances of Anyplex MTB/NTM Real-time detection vs Xpert® MTB/RIF Ultra for tuberculosis among people living with human immunodeficiency virus with low CD4 count
Year: 2025
Type: article
Study design: Observational Study
Abstract: • The respective performances of Anyplex and Xpert in PLHIV with low CD4 count were assessed. • The two assays showed similar MTC diagnostic performances in respiratory samples. • Anyplex showed higher specificity and lower sensitivity in non-respiratory samples. • The differences in diagnostic performance were observed based on CD4 count. The aim of this study was to evaluate the performances of Anyplex® MTB/NTM Real-time Detection and Xpert MTB/RIF Ultra for tuberculosis (TB) disease in people living with Human Immunodeficiency Virus (PLHIV) with low CD4 + T lymphocyte cell (CD4) count. A retrospective observational study included respiratory and non-respiratory specimens from PLHIV stratified based on their CD4 count (<200 vs. ≥ 200 cells/µL) using Anyplex® MTB/NTM Real-time Detection or Xpert® MTB/RIF Ultra. In PLHIV with low CD4 count (<200 cells/µL), Anyplex demonstrated comparable sensitivity (81.4 % vs. 81.8 %) and specificity (78.7 % vs. 78.5 %) to Xpert for MTC detection in respiratory samples, but lower sensitivity (81.8 % vs. 100 %) and higher specificity (83.3 % vs. 66.6 %) than Xpert in non-respiratory samples. Whereas the two methodologies showed similar MTC diagnostic performance in respiratory samples from PLHIV with low CD4 levels, Anyplex showed higher specificity and lower sensitivity than Xpert in non-respiratory samples.
Source: Infectious Diseases Now
Language: English
Subfield: Infectious Diseases
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $1,640
OpenAlex ID: W4416420391